The emerging role of incretins in the pathophysiology of insulin resistance in type 1 diabetes
| Autor: | Gorana Mirošević, Kristina Blaslov, Fran Naranđa, Mihovil Plećko, Jelena Marinković Radošević, Milan Vrkljan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
incretin system
insulin resistance type 1 diabetes glucagon-like peptide-1 dipeptidyl peptidase-4 endocrine system Type 1 diabetes digestive oral and skin physiology dipeptidylpeptidase-4 lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens lcsh:RC254-282 hormones hormone substitutes and hormone antagonists |
| Zdroj: | Endocrine Oncology and Metabolism, Vol 3, Iss 3, Pp 90-96 (2017) |
| DOI: | 10.21040/eom/2017.3.3.5 |
| Popis: | The pathophysiology of insulin resistance (IR) comprises a complex adipokine-mediated crosstalk between white adipose tissue and other organs. Although it is a prominent feature of Type 2 diabetes, a certain degree of IR also exists in Type 1 diabetes mellitus (T1DM). Incretins are gut derived hormones secreted into the circulation in response to nutrient ingestion that enhances glucose-stimulated insulin secretion. One of the main incretin hormones is glucagon-like peptide-1. It is degraded by dipeptidyl peptidase-4 (DPP-4) minutes after secretion. The diminished “incretin effect” is recognized as a part of prediabetes, usually associated with IR. DPP-4, as a part of the incretin system, has recently been proposed as a novel adipokine linked to IR and DPP-4 activity is higher in T1DM patients compared to healthy controls; furthermore, it correlates with the degree of IR. The role of the incretin system, with special emphasis on DPP-4, merits further evaluation because it might offer an insulin add-on therapeutic approach in the metabolic control of T1DM. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|